S&P Futures
4,158.50 -17.25 (-0.41%) Dow Futures
34,090.00 -116.00 (-0.34%) Nasdaq Futures
12,721.25 -55.50 (-0.43%) Russell 2000 Futures
1,968.40 -10.90 (-0.55%) Crude Oil
77.38 +0.24 (+0.31%) Gold
1,894.20 +9.40 (+0.50%)
Seelos Therapeutics, Inc. (SEEL)
After hours:
- PR Newswire
Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has dosed the first patients in an ethnobridging study in healthy adult Japanese and non-Asian subjects to compare the safety and pharmacokinetic profiles of SLS-002 (intranasal racemic ketamine). Seelos consulted and received endorsement from the Pharmaceuticals and Medical Devices Agency (PMD
- PR Newswire
Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 12th Annual LifeSci Partners Corporate Access Event, to be held in San Francisco, California on January 9-11th, 2023.
- Benzinga
Parkinson's Study Using CRISPR Technology Shows Promise, Seelos Therapeutics Says
Seelos Therapeutics Inc (NASDAQ: SEEL) announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein). This reduction of α-synuclein by SLS-004 in an established α-synuclein overexpressing animal model of Parkinson's disease (PD) resulted in a substantial increase and recovery of degeneration in tyrosine hydroxylase positive (TH+) dopaminergic neurons. TH+ dopaminergic neurons in the midbrain region, called substantia nigra pars c
